

AMENDMENTS TO THE CLAIMS


Claims 6 and 29 are amended herein. This listing of claims will replace all prior versions, and listings of claims, in the application.

Listing of Claims:

1-3. (Canceled).

4. (Previously Presented) A pharmaceutical composition comprising:

(a) a therapeutically-effective amount of the compound of formula I or a pharmaceutically acceptable salts thereof, wherein



Formula (I)

R₁ is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6;

R₂ is hydroxyl, sulfydryl, methylthio group, or ethylthio group at position 2, 3 or 4; and


(b) a pharmaceutically-acceptable excipient.

5. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the composition comprises 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

6. (Currently Amended) A The pharmaceutical composition according to claim 4, wherein the composition is formulated as a tablet, capsule, ampule or pill.

7. (Withdrawn) A method for producing the compound of formula I, comprising the steps of:

(a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200° C., thereby producing the compound of formula Ia;




wherein

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,

R_3 is $-\text{OCH}_3$, $-\text{SCH}_3$, $-\text{OC}_2\text{H}_5$ or $-\text{SC}_2\text{H}_5$ at position 2, 3 or 4, and

X is Cl, Br or I;

(b) reacting the compound of formula Ia and BBr_3 in an inert solvent at -10°C . to 15°C ., thereby producing the compound of formula I:



wherein, R_1 and R_3 are defined as above, and R_2 is $-\text{OH}$ or $-\text{SH}$.

8. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99 wt % of the compound of formula I, on the basis of the total weight.

9. (Withdrawn) Use of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. (Withdrawn) A method for treating fibrosis diseases, comprising administering a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.

11. (Previously Presented) The pharmaceutical composition according to claim 4, wherein R_1 is methyl, and R_2 is hydroxyl.

12. (Previously Presented) The pharmaceutical composition according to claim 4, wherein R_1 is methyl at position 5, and R_2 is hydroxyl at position 4.

13. (Cancelled).
14. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for oral, intravenous, intramuscular or subcutaneous administration.
15. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for oral administration.
16. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for external administration.
17. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the composition is formulated as an ointment, gel, or drug-containing rubber cement.
18. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for parenteral administration.
19. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the composition comprises 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.
- 20-21. (Cancelled).
22. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for slow release.
23. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the excipient is starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose, white bole or combinations thereof.
24. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the excipient is sterile water, polyethylene glycol, a nonionic surfactant, edible oil or combinations thereof.
25. (Previously Presented) The pharmaceutical composition according to claim 4, further comprising an adjuvant.
26. (Cancelled).
27. (Previously Presented) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for administration in 2-4 separated dosages per day.
28. (Previously Presented) The pharmaceutical composition according to claim 4, further comprising a flavoring agent, colorant, preservative, antioxidant, or combinations thereof.
29. (Currently Amended) The pharmaceutical composition according to claim 4, further comprising vitamin E, vitamin C, ~~BHT~~ butylated hydroxytoluene (BHT) and ~~BHA~~ butylated hydroxyanisole (BHA) or combinations thereof.